DE69841318D1 - Polyamin-behandlung von neurologischen störungen - Google Patents

Polyamin-behandlung von neurologischen störungen

Info

Publication number
DE69841318D1
DE69841318D1 DE69841318T DE69841318T DE69841318D1 DE 69841318 D1 DE69841318 D1 DE 69841318D1 DE 69841318 T DE69841318 T DE 69841318T DE 69841318 T DE69841318 T DE 69841318T DE 69841318 D1 DE69841318 D1 DE 69841318D1
Authority
DE
Germany
Prior art keywords
mptp
metals
xenobiotics
tetramine
dopamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841318T
Other languages
English (en)
Inventor
Michael A Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69841318D1 publication Critical patent/DE69841318D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
DE69841318T 1997-08-21 1998-08-21 Polyamin-behandlung von neurologischen störungen Expired - Lifetime DE69841318D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/915,660 US5906996A (en) 1996-08-21 1997-08-21 Tetramine treatment of neurological disorders
PCT/US1998/017301 WO1999008519A1 (en) 1997-08-21 1998-08-21 Polyamine treatment of neurological disorders

Publications (1)

Publication Number Publication Date
DE69841318D1 true DE69841318D1 (de) 2010-01-07

Family

ID=25436083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841318T Expired - Lifetime DE69841318D1 (de) 1997-08-21 1998-08-21 Polyamin-behandlung von neurologischen störungen

Country Status (11)

Country Link
US (1) US5906996A (de)
EP (1) EP1017275B1 (de)
JP (1) JP2001515012A (de)
CN (1) CN1216599C (de)
AT (1) ATE449536T1 (de)
AU (1) AU737484B2 (de)
CA (1) CA2339782C (de)
DE (1) DE69841318D1 (de)
EA (1) EA004400B1 (de)
HK (1) HK1029494A1 (de)
WO (1) WO1999008519A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342945A (en) * 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US6262125B1 (en) * 1986-12-02 2001-07-17 University Of Florida Research Foundation, Inc. Sterically hindered tetraamines and method for their production
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
EP1089734A2 (de) * 1998-06-26 2001-04-11 Georgetown University Medical Center Verwendung von tempo und tempoderivaten zur induktion des zellentodes
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) * 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
WO2000018392A1 (en) * 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
JP2002543163A (ja) * 1999-04-30 2002-12-17 スリル バイオメディカル コーポレイション 癌および前立腺疾患のための治療としての結合体
CA2371625C (en) * 1999-04-30 2012-04-17 Slil Biomedical Corporation Polyamines and their use in therapy
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
WO2001025265A1 (en) 1999-10-01 2001-04-12 Dmi Biosciences, Inc. Metal-binding compounds and uses therefor
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
AU2001297817A1 (en) * 2000-11-08 2002-11-25 Eli Lilly And Company Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
JP2005506096A (ja) * 2001-01-19 2005-03-03 ニューレンズ、エルエルシー 水晶体の変化による老眼治療
JP2005506354A (ja) * 2001-10-16 2005-03-03 スリル バイオメディカル コーポレイション 癌治療のためのオリゴアミン化合物およびその誘導体
EP1448183A2 (de) * 2001-11-16 2004-08-25 ALS Therapy Development Foundation, Inc. Behandlung von neurodegenerativen erkrankungen durch modulieren des polyaminenbiosynthesewegs
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
EP2500018B1 (de) 2002-03-08 2017-07-19 PhilERA New Zealand Limited Verhindern und/oder Behandeln der kardiovaskulären Erkrankung und/oder zugehöriges Herzversagen
AU2003251920A1 (en) * 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
CA2875095C (en) 2004-07-19 2019-09-03 Philera New Zealand Limited Synthesis of triethylenetetramines
US20110028513A1 (en) * 2008-03-31 2011-02-03 Lang Zhuo Method for treating neurological disorders with imidazolium and imidazolinium compounds
US20160010154A1 (en) * 2012-11-30 2016-01-14 The Parkinson's Institute Screening assays for therapeutics for parkinson's disease
EP3221330A4 (de) * 2014-11-18 2018-08-29 Zata Pharmaceuticals Inc. Phosphoramiditsynthone zur synthese von selbstneutralisierenden oligonukleotidverbindungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323558A (en) * 1979-09-10 1982-04-06 Nelson Research & Development Co. Topical trien containing pharmaceutical compositions and methods of use
US4728006A (en) 1984-04-27 1988-03-01 The Procter & Gamble Company Flexible container including self-sealing dispensing valve to provide automatic shut-off and leak resistant inverted storage
US5033655A (en) 1989-02-15 1991-07-23 Liquid Molding Systems Inc. Dispensing package for fluid products and the like
US5409144A (en) 1991-12-06 1995-04-25 Liquid Molding Systems Inc. Dispensing valve for packaging
US5213236A (en) 1991-12-06 1993-05-25 Liquid Molding Systems, Inc. Dispensing valve for packaging
US5494935A (en) * 1992-01-17 1996-02-27 University Of Utah Research Foundation Methods for oral decorporation of metals
JPH07118148A (ja) * 1993-10-26 1995-05-09 Tsumura & Co 肝癌予防剤

Also Published As

Publication number Publication date
AU9200698A (en) 1999-03-08
EP1017275A1 (de) 2000-07-12
AU737484B2 (en) 2001-08-23
CA2339782A1 (en) 1999-02-25
CN1271250A (zh) 2000-10-25
WO1999008519A1 (en) 1999-02-25
HK1029494A1 (en) 2001-04-06
JP2001515012A (ja) 2001-09-18
CN1216599C (zh) 2005-08-31
ATE449536T1 (de) 2009-12-15
CA2339782C (en) 2005-06-14
US5906996A (en) 1999-05-25
EP1017275A4 (de) 2002-12-18
EA004400B1 (ru) 2004-04-29
EA200000244A1 (ru) 2000-10-30
EP1017275B1 (de) 2009-11-25

Similar Documents

Publication Publication Date Title
DE69841318D1 (de) Polyamin-behandlung von neurologischen störungen
PT1530469E (pt) Forma de dosagem transdérmica que compreende um agente activo, um sal e uma forma de base livre de um antagonista
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
ATE286393T1 (de) Formulation von 5-ht agonisten
IL93556A0 (en) Stabilized nitric oxide-primary amine complexes useful as cardiovascular agents
TR201903603T4 (tr) Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri.
CA2246839A1 (en) Pharmaceutical compositions containing ampa receptor antagonists for treating dyskineslas associated with dopamine agonist therapy
NZ334186A (en) Neurotrophic heterocyclic esters and amides with an affinity to FKBP-type immunophilins
BR9912760A (pt) Usos de gama vinilgaba (gvg) e de uma composição que aumenta os nìveis de gaba do sistema nervoso central
KR910014350A (ko) 3-아미노피페리딘 유도체 및 관련 질소 함유 헤테로사이클릭 화합물
Axelrod The uptake and release of catecholamines and the effect of drugs
DK1127571T3 (da) Anvendelse af sertralin til at behandle posttraumatisk stresssygdom
ATE205493T1 (de) N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
RU2001111868A (ru) Антагонисты метаботропных глутаматных рецепторов (mglur5) для лечения боли и состояния тревоги
BG105112A (en) Agents with antidepressive effect
DK0687176T3 (da) Anvendelse af riluzol til behandling af AIDS-relaterede nervesygdomme
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
EA199901075A1 (ru) Лечение резистентности к инсулину средствами, стимулирующими секрецию гормона роста
DE69705035T2 (de) N-Azacycloalkylalkyldibenzothiophencarboxamide: spezifische Liganden für Dopaminrezeptorsubtypen
KR910018381A (ko) 개선된 에르골린-8-카복스아미드
DK1342410T3 (da) Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition